Nanotechnology-Driven Noninvasive and Targeted Therapies for Anaplastic Thyroid Carcinoma

Abstract

Anaplastic thyroid carcinoma (ATC) is a highly aggressive and treatment-resistant form of thyroid cancer, characterized by poor prognosis, rapid metastasis, and resistance to conventional therapies. Current treatment options, including surgery, chemotherapy, and radiation, are often ineffective in controlling the disease, underscoring the urgent need for novel therapeutic approaches. Nanotechnology has emerged as a promising strategy to overcome these challenges, offering innovative solutions for targeted drug delivery and noninvasive therapeutic modalities. This review explores the latest advancements in nanotechnology-driven strategies for treating ATC, with a particular focus on noninvasive therapies such as sonodynamic therapy and nano-pulse stimulation, as well as the development of nanomaterial-based drug delivery systems. These systems, including RNA-based nanocarriers, radionuclide-labeled nanoparticles, and nanoclay-based delivery systems, provide enhanced specificity and efficacy, overcoming the limitations of traditional treatments. Additionally, dual-modality theranostic systems, which combine diagnostic imaging and therapeutic payloads, hold great promise in improving early detection and real-time treatment monitoring. Despite the promising preclinical results, challenges such as tumor heterogeneity, drug resistance, and biocompatibility of nanomaterials remain in the clinical use. This review provides a comprehensive overview of the potential of nanotechnology to revolutionize the treatment of ATC, offering new hope for patients with this highly aggressive malignancy.

Impact Statement

The innovative use of nanotechnology in the treatment of anaplastic thyroid carcinoma (ATC) represents a transformative shift in cancer therapy, offering targeted, noninvasive, and highly effective alternatives to traditional treatment methods. By leveraging cutting-edge nanomaterials for precise drug delivery and integrating them with noninvasive therapeutic strategies such as sonodynamic therapy and nano-pulse stimulation, this review highlights the potential for significantly improving patient outcomes in ATC. The development of dual-modality theranostic systems that combine diagnosis and treatment within a single platform offers unparalleled opportunities for real-time monitoring and personalized treatment, addressing the critical challenge of early metastasis and therapeutic resistance in ATC. These advancements not only pave the way for more effective treatment options for ATC but also contribute to the broader field of cancer nanomedicine, setting the stage for more targeted and individualized therapies across various malignancies.